As a result, we believe that SW IV-134 could potentially be used to sensitize several additional sigma-2-expressing malignancies, including head and neck tumors, breast cancer, lymphomas [43], and ovarian cancer [22] to different chemotherapeutics. The gene discussed is AP2S1; the disease is ovarian carcinoma.